Literature DB >> 12709355

Susceptibilities of simian immunodeficiency virus to protease inhibitors.

Angelica C Giuffre1, Joanne Higgins, Robert W Buckheit, Thomas W North.   

Abstract

We used a focal infectivity assay with HeLa H1-JC.37 cells to directly compare susceptibilities of simian immunodeficiency virus (SIV) and human immunodeficiency virus type 1 (HIV-1) to protease inhibitors. SIVmac239 was inhibited by indinavir, saquinavir, and ritonavir, with 50% effective concentrations (means +/- standard deviations) of 39 +/- 8, 55 +/- 3, and 13 +/- 5 nM, respectively. The corresponding values for inhibition of HIV-1 were 66 +/- 4, 47 +/- 10, and 25 +/- 14 nM, respectively.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12709355      PMCID： PMC153320          DOI： 10.1128/AAC.47.5.1756-1759.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  46 in total

1.  Post-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV/HIV chimera.

Authors:  R Le Grand; B Vaslin; J Larghero; O Neidez; H Thiebot; P Sellier; P Clayette; N Dereuddre-Bosquet; D Dormont
Journal:  AIDS       Date:  2000-08-18       Impact factor: 4.177

2.  Detection and differentiation by sandwich enzyme-linked immunosorbent assay of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus- and acquired immunodeficiency syndrome-associated retroviruslike clinical isolates.

Authors:  J R Higgins; N C Pedersen; J R Carlson
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

3.  Antiviral effects of 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, and 2',3'-dideoxyadenosine against simian acquired immunodeficiency syndrome-associated type D retrovirus in vitro.

Authors:  C C Tsai; K E Follis; R E Benveniste
Journal:  AIDS Res Hum Retroviruses       Date:  1988-10       Impact factor: 2.205

4.  An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection.

Authors:  P Ashorn; T J McQuade; S Thaisrivongs; A G Tomasselli; W G Tarpley; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

5.  Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity.

Authors:  B Chesebro; K Wehrly
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

6.  Crystal structure of a retroviral protease proves relationship to aspartic protease family.

Authors:  M Miller; M Jaskólski; J K Rao; J Leis; A Wlodawer
Journal:  Nature       Date:  1989-02-09       Impact factor: 49.962

7.  Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection.

Authors:  K K Van Rompay; M G Otsyula; R P Tarara; D R Canfield; C J Berardi; M B McChesney; M L Marthas
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

8.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

9.  Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.

Authors:  A C Collier; R W Coombs; D A Schoenfeld; R L Bassett; J Timpone; A Baruch; M Jones; K Facey; C Whitacre; V J McAuliffe; H M Friedman; T C Merigan; R C Reichman; C Hooper; L Corey
Journal:  N Engl J Med       Date:  1996-04-18       Impact factor: 91.245

10.  Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.

Authors:  Jeffrey P Murry; Joanne Higgins; Timothy B Matthews; Victoria Y Huang; Koen K A Van Rompay; Niels C Pedersen; Thomas W North
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103
View more
  11 in total

1.  Ring substituent effects on biological activity of vinyl sulfones as inhibitors of HIV-1.

Authors:  D Christopher Meadows; Tino Sanchez; Nouri Neamati; Thomas W North; Jacquelyn Gervay-Hague
Journal:  Bioorg Med Chem       Date:  2006-10-30       Impact factor: 3.641

2.  HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription.

Authors:  Christine Goffinet; Ina Allespach; Oliver T Keppler
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-05       Impact factor: 11.205

3.  Direct inactivation of human immunodeficiency virus type 1 by a novel small-molecule entry inhibitor, DCM205.

Authors:  Yen T Duong; D Christopher Meadows; Indresh K Srivastava; Jacquelyn Gervay-Hague; Thomas W North
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

Review 4.  Can humanized mice reflect the complex pathobiology of HIV-associated neurocognitive disorders?

Authors:  Santhi Gorantla; Howard E Gendelman; Larisa Y Poluektova
Journal:  J Neuroimmune Pharmacol       Date:  2012-01-07       Impact factor: 4.147

5.  Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.

Authors:  Thomas W North; Koen K A Van Rompay; Joanne Higgins; Timothy B Matthews; Debra A Wadford; Niels C Pedersen; Raymond F Schinazi
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 6.  Simian immunodeficiency virus macaque models of HIV latency.

Authors:  Jesse D Deere; Raymond F Schinazi; Thomas W North
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

7.  Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics.

Authors:  Thomas W North; Andradi Villalobos; Selwyn J Hurwitz; Jesse D Deere; Joanne Higgins; Payel Chatterjee; Sijia Tao; Robert C Kauffman; Paul A Luciw; James J Kohler; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

8.  Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.

Authors:  Michael J Hofman; Joanne Higgins; Timothy B Matthews; Niels C Pedersen; Chalet Tan; Raymond F Schinazi; Thomas W North
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Simian immunodeficiency virus SIVagm dynamics in African green monkeys.

Authors:  Ivona Pandrea; Ruy M Ribeiro; Rajeev Gautam; Thaidra Gaufin; Melissa Pattison; Mary Barnes; Christopher Monjure; Crystal Stoulig; Jason Dufour; Wayne Cyprian; Guido Silvestri; Michael D Miller; Alan S Perelson; Cristian Apetrei
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

10.  Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS.

Authors:  Jesse D Deere; Joanne Higgins; Elda Cannavo; Andradi Villalobos; Lourdes Adamson; Emilie Fromentin; Raymond F Schinazi; Paul A Luciw; Thomas W North
Journal:  PLoS One       Date:  2010-07-23       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.